Pharmacology Research Today is a free monthly online journal that collates and summarizes the latest research about Pharmacology, including details on pharmacogenomics, drug development, new medications.

Volume 2 (2006), Issue 5 (May)

1. Effect of the difference in vehicles on gene expression in the rat liver--analysis of the control data in the Toxicogenomics Project Database.
   Life Sci, 78(24): 2787-96. [Abstract] [Full-text]
2. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration.
   Med Care Res Rev, 63(3): 301-26. [Abstract] [Full-text]
3. Pharmacogenomics: from bedside to clinical practice.
   Hum Mol Genet, 15: R89-93. [Abstract] [Full-text]
4. Application of SPLINDID, a semiparametric, model-based method for pharmacogenomic modeling of mRNA dynamics.
   Pharm Res, 23(4): 663-9. [Abstract] [Full-text]
5. In silico pharmacogenetics of warfarin metabolism.
   Nat Biotechnol, 24(5): 531-6. [Abstract] [Full-text]
6. Pharmacogenetic studies of epilepsy drugs: are we there yet?
   Trends Genet, 22(5): 250-2. [Abstract] [Full-text]
7. Competitive allele-specific short oligonucleotide hybridization (CASSOH) with enzyme-linked immunosorbent assay (ELISA) for the detection of pharmacogenetic single nucleotide polymorphisms (SNPs).
   J Biochem Biophys Methods, 67(2): 87-94. [Abstract] [Full-text]
8. Mass spectrometry in toxinology: a 21st-century technology for the study of biopolymers from venoms.
   Toxicon, 47(6): 609-13. [Abstract] [Full-text]
9. Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the Netherlands.
   Pharmacoepidemiol Drug Saf, 15(5): 338-43. [Abstract] [Full-text]
10. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics.
    Pharmacoepidemiol Drug Saf, 15(5): 291-303. [Abstract] [Full-text]
11. Estimation of time-dependent rate ratios in case-control studies: comparison of two approaches for exposure assessment.
    Pharmacoepidemiol Drug Saf, 15(5): 304-16. [Abstract] [Full-text]
12. Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays.
    Nat Clin Pract Oncol, 3(5): 256-68. [Abstract] [Full-text]
13. David Kupfer at meetings and play.
    Drug Metab Rev, 38(1): 163-70. [Abstract] [Full-text]
14. A photographic diary of travels with David Kupfer.
    Drug Metab Rev, 38(1): 23-9. [Abstract] [Full-text]
15. David Kupfer, Ph.D. A mentor and a scientist.
    Drug Metab Rev, 38(1): 13-22. [Abstract] [Full-text]
16. Computational neuropharmacology: dynamical approaches in drug discovery.
    Trends Pharmacol Sci, 27(5): 240-3. [Abstract] [Full-text]
17. Principles: when there should be no difference--how to fail to reject the null hypothesis.
    Trends Pharmacol Sci, 27(5): 274-8. [Abstract] [Full-text]
18. Molecular biology of the nasal airways: how do we assess cellular and molecular responses in the nose?
    Toxicol Pathol, 34(3): 274-80. [Abstract] [Full-text]
19. Establishment of cell-free electrophysiology for ion transporters: application for pharmacological profiling.
    J Biomol Screen, 11(3): 262-8. [Abstract] [Full-text]
20. Development of the chromatographic fingerprint of herbal preparations Shuang-Huang-Lian oral liquid.
    J Pharm Biomed Anal, 41(3): 845-56. [Abstract] [Full-text]
21. Magnetoencephalography (MEG): a non-invasive tool for studying cortical effects in psychopharmacology.
    Int J Neuropsychopharmacol, 9(3): 367-72. [Abstract] [Full-text]
22. Next revolution in the molecular theranostics of infectious diseases: microfabricated systems for personalized medicine.
    Expert Rev Mol Diagn, 6(3): 433-50. [Abstract] [Full-text]
23. AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.
    Expert Rev Mol Diagn, 6(3): 277-86. [Abstract] [Full-text]
24. Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine.
    Pharmacogenomics J, 6(3): 162-5. [Abstract] [Full-text]
25. Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics.
    Pharmacogenomics J, 6(3): 174-8. [Abstract] [Full-text]
26. Building an ontology of adverse drug reactions for automated signal generation in pharmacovigilance.
    Comput Biol Med, 36(7): 748-67. [Abstract] [Full-text]

© 2005-2013 Pharmacology Research Today. All Rights Reserved.